I am a cancer biologist determining the mechanisms controlling growth and proliferation of cancer cells and use transgenic models of malignancy and genetic approaches to identify new therapies for targeting growth control in the treatment of cancer.
Prof Lindeman's laboratory, co-headed with Dr Visvader, has played an influential role in the identification of mammary stem and progenitor cells, elucidation of the mammary epithelial cell hierarchy and gaining insights into how female hormones regulate mammary gland development and cancer. In parallel, I have established translational research platforms such as patient-derived tumour xenograft (PDX) models, which offer powerful preclinical models to test new drugs.
I am a cell biologist/geneticist focusing on understanding tumourigenesis. Cancer is a multigenic and complicated disease, involving interactions between the tumour and normal tissue. I use the genetically tractable model organism, the vinegar fly, Drosophila, to model cancer in situ and identify novel genes that drive cancer. My 5 year career plan is to use the Drosophila system to model cooperative tumourigenesis in epithelial and brain tissues and translate this to human cancer.
Molecular Mechanisms And Functional Consequences - Understanding Endocrine Tumorigenesis
Funder
National Health and Medical Research Council
Funding Amount
$124,530.00
Summary
A/Prof Marsh is focused on discovering the causes of both inherited and non-inherited endocrine tumours, translating this knowledge into medical practice for the improved diagnosis of cancer and using this knowledge to highlight new therapeutic options for people who have cancer. She is internationally recognised for her work on a protein linked to the development of parathyroid cancer and is working towards improving our understanding of women’s cancers.
Strategies For Enhancing The Treatment Of Colon Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$590,785.00
Summary
Colorectal cancer is the third leading cause of cancer related death in Australia. Strategies to improve outcomes for these patients are urgently needed. This NHMRC SRF Fellowship will seek to identify new molecules in cancer cells which can be targeted to treat this disease, and to discover genes which can be used to improve patient response to treatment.
Human Pigmentation Genetics, Melanocyte Biology And Skin Cancer
Funder
National Health and Medical Research Council
Funding Amount
$686,656.00
Summary
The fellowship application by A/Prof Sturm is to support his research into the biology of human skin, hair and eye colour, and the process of melanoma formation. His pivotal discoveries into the genetic basis of pigmentation and its regulation has provided an understanding of these physical traits and the associated genotypic risk factors for skin cancer development. The genes that determine an individual's skin phototype and the mechanisms involved in the tanning response after UV-exposure of t ....The fellowship application by A/Prof Sturm is to support his research into the biology of human skin, hair and eye colour, and the process of melanoma formation. His pivotal discoveries into the genetic basis of pigmentation and its regulation has provided an understanding of these physical traits and the associated genotypic risk factors for skin cancer development. The genes that determine an individual's skin phototype and the mechanisms involved in the tanning response after UV-exposure of the skin are actively being investigated.Read moreRead less
Therapeutic Targeting Of Ribosome Biogenesis In Cancer And Ribosomopathies
Funder
National Health and Medical Research Council
Funding Amount
$763,845.00
Summary
My fellowship application will build on my international leadership in understanding growth control in human disease. My vision is to uncover the molecular mechanisms governing the loss of normal control of the synthesis of the molecular machines, termed ribosomes, that are responsible for synthesising all cell proteins. I will translate these findings into new paradigms to treat patients suffering from diseases such as cancer and ribosomopathies, that are associated with ribosome dysfunction.
Manipulating Oncogene Addiction And Immunity In The Treatment Of Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$687,975.00
Summary
Melanoma is a major Australian health problem and a common cause of cancer death in young adults. Treatment of melanoma has been revolutionised in the last few years, but many patients fail to respond to new therapies or rapidly progress on treatment. This proposal examines the mechanisms that drive resistance to therapy and identifies markers predictive of clinical response. This approach will accelerate the development of new strategies and improve patient care by personalising treatment.
Biosensor Imaging In Preclinical Pancreatic Cancer Targeting: Taking Cancer Targeting To New Dimensions.
Funder
National Health and Medical Research Council
Funding Amount
$640,210.00
Summary
Using cutting-edge imaging technology and 3D models that mimic cancer, we can map areas of poor drug response within distinct 'stages' or regions of tumours. Here, we pinpoint and specifically target key factors limiting efficient drug response in order to improve the encouraging anti-cancer profile of new or current drugs in pancreatic cancer.
Defining The Role Of The PSA-related Kallikrein Serine Proteases In Hormone Dependent Cancer Progression
Funder
National Health and Medical Research Council
Funding Amount
$880,454.00
Summary
Kallikreins are a family of 15 proteins, related to the prostate cancer biomarker PSA, that have potential as biomarkers for hormone dependent cancers such as prostate and ovarian cancer. Prof Judith Clements and her team discovered that kallikreins induce resistance to chemotherapy in ovarian cancer and are found in prostate cancer bone disease. Her research will determine the underlying mechanisms of kallikrein action and their potential as new biomarkers or treatment targets for these disease ....Kallikreins are a family of 15 proteins, related to the prostate cancer biomarker PSA, that have potential as biomarkers for hormone dependent cancers such as prostate and ovarian cancer. Prof Judith Clements and her team discovered that kallikreins induce resistance to chemotherapy in ovarian cancer and are found in prostate cancer bone disease. Her research will determine the underlying mechanisms of kallikrein action and their potential as new biomarkers or treatment targets for these diseases.Read moreRead less